We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Performance Evaluated for Point-of-Care HbA1c Analyzer

By LabMedica International staff writers
Posted on 07 Jul 2015
Print article
The SD A1cCare point-of-care analyzer
The SD A1cCare point-of-care analyzer (Photo courtesy of SD BIOSENSOR)
Glycated hemoglobin (HbA1c) levels, which reflect the average plasma glucose concentration over the preceding three months, play a pivotal role in the diagnosis, assessment, and monitoring of diabetes.

The immediate feedback of HbA1c levels is highly effective for controlling plasma glucose levels and point-of-care (POC) instruments, characterized as fast, portable, and easy-to-use, have been shown to be suitable for providing rapid feedback of HbA1c levels.

Medical laboratory scientists at the Seoul National University College of Medicine (Republic of Korea) assessed the analytical performance of a newly developed POC HbA1c analyzer. To investigate the accuracy of the analyzer, they measured the deviation from the International Federation of Clinical Chemistry (IFCC) reference targets using two sets of 12 duplicate fresh venous whole blood specimens with a range of 33.3 mmol/mol to 91.3 mmol/mol in International System of Units (SI) units, or 5.2% to 10.5% in National Glycohemoglobin Standardization Program (NSGP) units.

The SD A1cCare analyzer (SD Biosensor, Inc.; Suwon, Korea), which utilizes an immunochromatography assay, was used to measures total hemoglobin and HbA1c levels via its optical system and calculates the percentage HbA1c. The SD A1cCare Test kit uses an anti-HbA1c antibody that is specific for the first few amino acid residues of the glycated N-terminus of the β-chain of hemoglobin A0. The scientists tested 150 residual specimens using both the SD A1cCare and the Variant II Turbo (Bio-Rad Laboratories, Inc.; Hercules, CA, USA) in 14 days.

The SD A1cCare POC HbA1c analyzer showed excellent precision, linearity and correlation with Variant II Turbo high-performance liquid chromatography (HPLC) and it showed excellent accuracy with IFCC targets. Deviations from IFCC targets at 30, 60, and 90 mmol/mol IFCC levels were − 1.95, − 1.85, and − 1.74 mmol/mol, respectively. The coefficients of variation based on EP9-A2 protocol were 2.6% in SI units and 1.8% in NGSP units.

The authors concluded that the SD A1cCare analyzer showed excellent precision, linearity, correlation with the Variant II Turbo analyzer, and accuracy with IFCC targets and therefore, it may be suitable for HbA1c assays in the POC setting and in small laboratories. The study was published in the June, 2015 issue of the journal Clinical Biochemistry.

Related Links:

Seoul National University College of Medicine 
SD Biosensor Inc.
Bio-Rad Laboratories 


Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Complement 3 (C3) Test
GPP-100 C3 Kit
New
Gold Member
Plasma Control
Plasma Control Level 1
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get complete access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more

Pathology

view channel
Image: The new AI tool can help beat brain tumors (Photo courtesy of Crystal Light/Shutterstock)

New AI Tool Classifies Brain Tumors More Quickly and Accurately

Precision in diagnosing and categorizing tumors is essential for delivering effective treatment to patients. Currently, the gold standard for identifying various types of brain tumors involves DNA methylation-based... Read more